CurrentCapital BluecrossPolicy MP 2.320

Genetic Testing for Alpha Thalassemia

Coverage and medical necessity guidance for genetic testing to diagnose or screen for alpha (α) thalassemia, and for prognostic testing in hemoglobin H disease; applies to Capital BlueCross products where specified.

Policy Summary

PayerCapital Bluecross

PolicyGenetic Testing for Alpha Thalassemia

Policy CodePolicy MP 2.320

Change TypeMinor editorial and coding revisions (history includes material coding/MN change)

Effective Date11/1/2025

Next Review DateN/A

Key ActionObtain and document prior biochemical testing (CBC, peripheral smear, hemoglobin electrophoresis) showing evidence suggestive of α-thalassemia before ordering genetic carrier testing.

SourceLink

POLICY UPDATE CHANGES

Editorial refinements to medical necessity criteria to state that testing is for Preconception (carrier) testing; NMN statement changed to INV.

Modified medical necessity (MN) statement during 07/14/2022 minor review and updated coding by removing CPT 81361-81364 for beta thalassemia.

12/18/2023 consensus review updated references with no changes to coding.

~5%global prevalence

1 in 20SE Asian carrier rate

25%Risk of Hemoglobin Bart's (both parents trait)

90%

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

S3845, 81257-81269Covered codes listed

Coverage Criteria

Preconception (carrier) testing — covered when ALL criteria met

Covered when ALL criteria met:

Medically necessary preconception testing: Preconception (carrier) testing for α-thalassemia in prospective parents is considered medically necessary when BOTH parents have biochemical evidence suggestive of possible α-thalassemia (including α-thalassemia minor, hemoglobin H disease, or α-thalassemia minima) based on biochemical testing (CBC, peripheral smear, hemoglobin electrophoresis)both parents with biochemical evidence

Prenatal (in utero) and preimplantation genetic testing are not addressed in this policy.

Investigational indications

Not covered / investigational:

Investigational indications: Genetic testing to confirm a diagnosis of α-thalassemia; genetic testing of individuals with hemoglobin H (α-thalassemia intermedia) to determine prognosis; genetic testing for α-thalassemia in other clinical situations (excluding prenatal)N/A

These uses are considered investigational due to insufficient evidence of benefit.

Preconception (carrier) testing - Medical Necessity

Covered when ALL of the following are met:

Preconception carrier testing for α-thalassemia is considered medically necessary to determine risk of hemoglobin Bart's (hydrops fetalis) for prospective parents when biochemical screening suggests carrier status or for populations at increased risk.N/A

Biochemical screening (CBC, peripheral smear, hemoglobin electrophoresis) is the first-line evaluation; genetic testing more precisely determines number of abnormal HBA1/HBA2 genes and refines reproductive risk assessment.

Genetic testing for suspected alpha thalassemia or HbH disease

Not sufficiently supported for routine use:

Diagnostic genetic testing for suspected disease: Genetic testing for individuals with suspected α-thalassemia or with hemoglobin H disease has insufficient evidence to demonstrate improvement in net health outcomes; many α-thalassemia syndromes can be diagnosed by biochemical testing alone.N/A

Although genotype-phenotype correlations exist, current evidence does not indicate that genetic results change patient management or outcomes.

This policy does not address prenatal (in utero) or preimplantation genetic testing for alpha thalassemia. Refer to program-specific policies for invasive prenatal diagnostic testing or preimplantation genetic testing when those services are being considered.

Genetic testing is not required for diagnosis in many α-thalassemia syndromes because biochemical testing (CBC, peripheral smear, hemoglobin electrophoresis) is the recommended first-step evaluation and can establish the diagnosis in trait and silent carrier states.

Genetic testing to confirm a diagnosis of α-thalassemia and genetic testing of individuals with hemoglobin H (HbH) disease for prognostic purposes are considered investigational. The evidence is insufficient to demonstrate that genetic testing for these indications improves clinical health outcomes or alters management.

Genetic testing for suspected alpha thalassemia or HbH disease is considered investigational/insufficient for routine diagnostic use because diagnosis can often be made based on biochemical testing, and current evidence does not show that genetic results change patient management or improve outcomes.

Covered Indications

Preconception carrier testing when both prospective parents have biochemical evidence suggesting possible α-thalassemia.

Covered when BOTH prospective parents have biochemical evidence suggestive of α-thalassemia:

Both parents with biochemical evidence: Both prospective parents have biochemical evidence suggestive of α-thalassemia as documented by abnormal complete blood count and peripheral smear, with or without supportive hemoglobin electrophoresis findings.both parents with biochemical evidence

Documentation of prior biochemical testing is required before genetic testing for preconception carrier assessment.

Biochemical testing first step: Biochemical testing (CBC, peripheral smear, hemoglobin electrophoresis) should be performed and documented prior to consideration of genetic testing for carrier/preconception purposes.N/A

Hemoglobin electrophoresis may be normal in silent carriers and in α-thalassemia trait; CBC and peripheral smear should show evidence suggestive of possible α-thalassemia.

Coding

Covered when medically necessary; preconception (carrier) testingmixedCovered

S3845	Listed procedure code grouping for genetic testing (payer-specific)
81257	Procedure Code listed in policy
81258	Procedure Code listed in policy
81259	Procedure Code listed in policy
81269	Procedure Code listed in policy
D56.0	Alpha thalassemia
D56.3	Thalassemia minor
Z31.430	Encounter of female for testing for genetic disease carrier status for procreative management
Z31.440	Encounter of male for testing for genetic disease carrier status for procreative management

Deletion prevalence

Deletion prevalenceApproximately 90% of alpha‑thalassemia cases are due to deletions of one or more α‑globin genes.

Other variant typesSingle‑nucleotide variants and large rearrangements also occur and account for the remainder of cases.

Testing methods relevant to deletionsPCR and targeted deletion assays (including multiplex amplification and real‑time PCR) are commonly used to detect deletion‑type defects.

Provider Actions & Billing

Prior Authorization

Product-specific prior authorization

Policy applicability varies by product. This genetic testing policy applies only to certain programs and products administered by Capital BlueCross and is subject to benefit variations. Check member benefits and program-specific guidance (for example, the FEP PPO Medical Policy Manual) for prior authorization and coverage requirements before ordering testing.

Check member benefit information to confirm coverage and prior authorization requirements.
FEP PPO: refer to the FEP Medical Policy Manual for program-specific requirements.

Step Therapy

Stepwise testing requirement

Biochemical testing is required as the first-step evaluation before genetic testing for alpha-thalassemia. Document the results of initial biochemical studies (CBC, peripheral smear, hemoglobin electrophoresis) showing evidence suggestive of alpha-thalassemia prior to submission of genetic testing for preconception carrier evaluation.

Required first-step tests: complete blood count (CBC), peripheral smear, hemoglobin electrophoresis.

Eligibility Requirements

Eligibility requirements for this policy are specified in the coverage criteria sections. There are no additional top-level eligibility nodes in this policy.

No additional eligibility requirements are defined beyond those in the medical necessity criteria and documentation sections of the policy.

There are no separate prior-testing or family-history thresholds listed as top-level eligibility requirements in this policy.

This policy does not include extra eligibility nodes; coverage is determined by the medical necessity criteria and member benefit information.

Not Covered / Investigational

NOT COVERED: Genetic testing to confirm a diagnosis of α-thalassemia and genetic testing for prognostic purposes in hemoglobin H disease are considered investigational and are not covered for routine diagnostic or prognostic use. Preconception carrier testing remains the covered indication when medical necessity criteria are met.

NOT COVERED: Genetic testing for diagnostic purposes in individuals with suspected alpha thalassemia or HbH disease lacks sufficient evidence to demonstrate improved health outcomes and is therefore considered investigational/insufficient for routine diagnostic use.

Background

BACKGROUND: Alpha-thalassemia is a group of inherited disorders caused by reduced production of α-globin chains due to pathogenic variants in the HBA1 and HBA2 genes (four gene copies total). Clinical phenotypes range from a silent carrier state to hemoglobin Bart’s (α-thalassemia major), with intermediate forms such as thalassemia trait and hemoglobin H (HbH) disease. Severity is influenced by the number and type of affected α-globin genes; deletion-type defects account for approximately 90% of cases and over 100 variants have been described.

Definitions

Silent carrier (α‑thalassemia minima)

DefinitionSilent carrier (α‑thalassemia minima) — genotype αα/α‑ (one abnormal α gene); typically a silent carrier state.

Laboratory findingsMay show mild hypochromia and microcytosis; usually no anemia and hemoglobin electrophoresis is typically normal or shows minimal changes.

Clinical significanceGenerally asymptomatic; most individuals do not require treatment but identification is relevant for reproductive risk assessment.

Thalassemia trait (α‑thalassemia minor)

DefinitionThalassemia trait (α‑thalassemia minor) — loss of two α‑globin genes (genotypes αα/-- or α-/α-); causes mild anemia.

HematologyRed blood cells are hypochromic and microcytic; hemoglobin electrophoresis is often normal.

Policy Summary

PayerCapital Bluecross

PolicyGenetic Testing for Alpha Thalassemia

Policy CodePolicy MP 2.320

Change TypeMinor editorial and coding revisions (history includes material coding/MN change)

Effective Date11/1/2025

Next Review DateN/A

Key ActionObtain and document prior biochemical testing (CBC, peripheral smear, hemoglobin electrophoresis) showing evidence suggestive of α-thalassemia before ordering genetic carrier testing.

SourceLink

On This Page

Preconception (carrier) testing in prospective parents to determine risk of hemoglobin Bart's (hydrops fetalis).

Covered when medically necessary to determine risk of hemoglobin Bart's (hydrops fetalis):

Preconception carrier testing to assess risk of Hemoglobin Bart's: Preconception (carrier) testing is considered medically necessary for prospective parents to determine the risk of hemoglobin Bart's (α-thalassemia major/hydrops fetalis) when biochemical screening suggests carrier status or when population risk indicates screening.N/A

Use the listed procedure and diagnosis codes for billing (see coding section). Genetic testing can determine the number of abnormal HBA1/HBA2 genes and more precisely estimate risk of hydrops fetalis.

In silent carriers and trait, hemoglobin electrophoresis may be normal; CBC and smear should show evidence suggestive of alpha-thalassemia.

Documentation Required

Required documentation

Documentation supporting medical necessity must be submitted with requests for preconception (carrier) genetic testing. Approval is dependent on demonstration of biochemical evidence suggestive of alpha-thalassemia in the individual(s) to be tested and on member benefit coverage.

Include results of CBC, peripheral smear, and hemoglobin electrophoresis that indicate possible alpha-thalassemia.
Indicate whether testing is for preconception carrier assessment and document both parents' biochemical evidence when applicable.
Coverage determination is subject to member benefit variation; presence of a code in the coding section does not guarantee coverage.

Denial Risk

Denial triggers

Genetic testing for alpha-thalassemia is covered only for preconception carrier testing when medical necessity criteria are met; genetic testing to confirm a diagnosis of alpha-thalassemia or in other clinical situations is considered investigational and may be denied. Coverage decisions are made based on medical necessity and member benefits.

Genetic testing to confirm a diagnosis of α-thalassemia or for prognosis in hemoglobin H disease is considered investigational — may result in denial.
Identification of procedural or diagnostic codes in the policy does not imply coverage; verify member benefits.
Preconception (carrier) testing is covered when both prospective parents have biochemical evidence suggestive of alpha-thalassemia and documentation is provided.

Note

Provider actions: genetic counseling

Genetic counseling is recommended prior to ordering genetic testing for inherited conditions. Counseling should be provided by an individual experienced in genetic medicine to assist with understanding test implications and reproductive decision making.

Formal genetic counseling is recommended when genetic testing for an inherited condition is considered.
Preconception carrier testing is intended to inform reproductive decision making; counseling may alter testing utilization and should be documented.

Clinical courseUsually asymptomatic or mild clinical effects; important for partner carrier screening in reproductive planning.

Hemoglobin H (HbH) disease (α‑thalassemia intermedia)

DefinitionHemoglobin H (HbH) disease (α‑thalassemia intermedia) — three abnormal α‑globin genes (α-/--); results in moderate‑to‑severe anemia with variable severity.

Clinical variabilityMarked phenotypic variability; most have mild disease, but some develop significant complications including hepatosplenomegaly and hemolytic anemia.

Transfusion riskAn estimated ~25% of patients may require transfusion support during their lifetime.

Hemoglobin Bart's (α‑thalassemia major)

DefinitionHemoglobin Bart's (α‑thalassemia major) — variants in all four α‑globin genes (--/--) causing hydrops fetalis and high risk of intrauterine or perinatal death.

Obstetrical risksAssociated maternal complications include hypertension, preeclampsia, antepartum hemorrhage, renal failure, premature labor, and placental abruption.

OutcomeOften results in intrauterine death or death shortly after birth without intervention.

Hemoglobin Bart's (genetic basis)

Genetic basisHemoglobin Bart's (α‑thalassemia major) results from variants in all four α‑globin genes (--/--) that prevent α‑globin production.

PathophysiologyAbsence of α‑globin chains leads to formation of nonfunctional hemoglobins and fetal hydrops.

Clinical implicationIdentifying parental carrier status is critical for reproductive risk assessment to prevent hydrops fetalis outcomes.

Hemoglobin H disease (clinical syndrome)

Syndrome descriptionHemoglobin H disease (α‑thalassemia intermedia) is a clinical syndrome characterized by chronic hemolytic anemia with variable complications such as hepatosplenomegaly and possible transfusion dependence.

Genotype influenceGenotype (deletion vs nondeletion variants) influences severity; nondeletion variants often cause earlier and more severe disease.

Management implicationsSome patients require ongoing monitoring for anemia, iron overload, and complications; transfusion support may be needed in a subset of patients.